-
Kenya's economy faces climate change risks: World Bank
-
From rations to G20's doorstep: Poland savours economic 'miracle'
-
Rural India powers global AI models
-
Equities, metals, oil rebound after Asia-wide rout
-
Italy's spread-out Olympics face transport challenge
-
Paying for a selfie: Rome starts charging for Trevi Fountain
-
Musk merges xAI into SpaceX in bid to build space data centers
-
New York records 13 cold-related deaths since late January
-
In post-Maduro Venezuela, pro- and anti-government workers march for better pay
-
Late-January US snowstorm wasn't historically exceptional: NOAA
-
Punctuality at Germany's crisis-hit railway slumps
-
Europe observatory hails plan to abandon light-polluting Chile project
-
Oil slides, gold loses lustre as Iran threat recedes
-
Russian captain found guilty in fatal North Sea crash
-
Disney earnings boosted by theme parks, as CEO handover nears
-
France demands 1.7 bn euros in payroll taxes from Uber: media report
-
Latest Epstein file dump rocks UK royals, politics
-
More baby milk recalls in France after new toxin rules
-
Germany hit by nationwide public transport strike
-
WHO chief says turmoil creates chance for reset
-
European stocks rise as gold, oil prices tumble
-
Trump says US talking deal with 'highest people' in Cuba
-
Olympic Games in northern Italy have German twist
-
At Grammys, 'ICE out' message loud and clear
-
Steven Spielberg earns coveted EGOT status with Grammy win
-
Kendrick Lamar, Bad Bunny, Lady Gaga triumph at Grammys
-
Japan says rare earth found in sediment retrieved on deep-sea mission
-
Oil tumbles on Iran hopes, precious metals hit by stronger dollar
-
Kendrick Lamar, Bad Bunny, Lady Gaga win early at Grammys
-
Surging euro presents new headache for ECB
-
US talking deal with 'highest people' in Cuba: Trump
-
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades
-
Hans Vestberg, Former Verizon Chairman and CEO, Joins Digipower X As Senior Advisor
-
Nigeria's president pays tribute to Fela Kuti after Grammys Award
-
Iguanas fall from trees in Florida as icy weather bites southern US
-
French IT giant Capgemini to sell US subsidiary after row over ICE links
-
New Epstein accuser claims sexual encounter with ex-prince Andrew: report
-
Snowstorm disrupts travel in southern US as blast of icy weather widens
-
Afghan returnees in Bamiyan struggle despite new homes
-
Mired in economic trouble, Bangladesh pins hopes on election boost
-
Chinese cash in jewellery at automated gold recyclers as prices soar
-
Nvidia boss insists 'huge' investment in OpenAI on track
-
Snowstorm barrels into southern US as blast of icy weather widens
-
Ex-prince Andrew again caught up in Epstein scandal
-
How Lego got swept up in US-Mexico trade frictions
-
Snow storm barrels into southern US as blast of icy weather widens
-
Ex-prince Andrew dogged again by Epstein scandal
-
'Malfunction' cuts power in Ukraine. Here's what we know
-
Women in ties return as feminism faces pushback
-
Ship ahoy! Prague's homeless find safe haven on river boat
Bayer sets aside more cash to deal with weedkiller woes
German pharmaceutical and agricultural chemicals giant Bayer said it had put aside an extra 1.2 billion euros ($1.4 billion) to deal with long-running US legal woes linked to a weedkiller.
It takes to 1.7 billion euros the amount set aside to deal with litigation linked to the glyphosate-based Roundup weedkiller, the German group said in a statement late Thursday.
Bayer also said it had achieved a "major settlement" with a law firm "reducing the total number of unresolved glyphosate claims to 61,000".
This means that a total of 131,000 claims had so far either been settled or deemed not eligible, it said.
The flood of legal cases in the United States relates to claims that the weedkiller causes blood cancer. Bayer says scientific studies and regulatory approvals show that the weedkiller is safe.
The Leverkusen-based group has already spent over $10 billion to settle cases.
Despite the extra provision for the legal cases, Bayer hiked its forecasts for 2025 due to a better-than-expected performance in its pharmaceuticals division.
The maker of Aspirin now expects sales of 46 to 48 billion euros this year up from a previous forecast of 45 to 47 billion.
It also predicted earnings before interest, taxes, depreciation and amortisation -- a key measure of profitability -- of 9.7 to 10.2 billion euros up from a previous forecast of 9.5 to 10 billion.
Its shares were up two percent on the blue-chip DAX index in Frankfurt Friday, while the broader index slipped 1.8 percent.
U.Ndiaye--CPN